Where Is The Patient Voice In Alzheimer's Disease Drug Development?
This article was originally published in Scrip
Executive Summary
Companies developing treatments for Alzheimer's disease and other types of dementia are failing to incorporate the patient voice in their drug development plans, said Marc Wortmann, Executive Director, Alzheimer's Disease International, in an interview with Scrip.